New platelet glycoprotein IIb/IIIa inhibitor trials in percutaneous coronary intervention

Journal of Invasive Cardiology

Volumn 11, Issue SUPPL. C, 1999, Pages

  Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY;

EID: 4243426766     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
2. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-1435.
3. Topol EJ, Byzova T, Plow EF. Of platelets, integrin ocllb β3 and GP IIb/IIIa blockers: Past, present and future perspectives. Lancet 1999;353:227-231.